Paradigm Biopharmaceuticals Ltd (ASX:PAR)'s Paul Rennie speaks to Proactive following the news it's received Investigational New Drug (IND) application approval from the US Food and Drug Administration (FDA) for a phase 3 clinical trial investigating its proprietary drug Zilosul® – formulated from Pentosan Polysulphate Sodium (PPS) – for the treatment of pain associated with knee osteoarthritis. He says the opening of the trial in the USA, the largest global pharmaceutical market, is a major milestone for the company.
Paradigm Biopharma seeing commercial interest as its gets FDA approval for pivotal phase 3 trial
